Extreme leanness, lower skeletal muscle quality, and loss of muscle mass during treatment are predictors of poor prognosis in cervical cancer treated with concurrent chemoradiation therapy

• Published in: International journal of clinical oncology Vol. 27; no. 5; pp. 983 - 991
• Main Authors: Abe, Akiko, Yuasa, Masao, Imai, Yoshie, Kagawa, Tomohiro, Mineda, Ayuka, Nishimura, Masato, Tonoiso, Chisato, Kubo, Akiko, Kawanaka, Takashi, Ikushima, Hitoshi, Iwasa, Takeshi
• Format: Journal Article
• Language: English
• Published: Singapore Springer Nature Singapore 01.05.2022; Springer Nature B.V
• Subjects: Adipose tissue; Adult; Aged; Aged, 80 and over; Body mass index; Body weight; Cancer Research; Cancer therapies; Cervical cancer; Cervix; Chemoradiotherapy; Chemoradiotherapy - adverse effects; Chemotherapy; Female; Human papillomavirus; Humans; Medical prognosis; Medicine; Medicine & Public Health; Metastases; Middle Aged; Muscle, Skeletal - pathology; Musculoskeletal system; Nutritional status; Oncology; Original Article; Papillomavirus Infections - pathology; Papillomavirus Vaccines; Patients; Prognosis; Radiation therapy; Retrospective Studies; Sarcopenia; Skeletal muscle; Surgical Oncology; Survival; Thinness - pathology; Toxicity; Uterine Cervical Neoplasms - pathology; Uterine Cervical Neoplasms - therapy; Vaccination; Skeletal muscle index; Sarcopenia; Intramuscular adipose tissue content; Prognosis; Concurrent chemoradiotherapy; Cervical cancer
• ISSN: 1341-9625; 1437-7772
• DOI: 10.1007/s10147-022-02140-w

Background Human papillomavirus vaccination is not widespread in Japan, and the low screening rates result in many cases of locally advanced cervical cancer. We investigated the prognostic significance of sarcopenia in patients with cervical cancer to guide healthcare policies to improve treatment outcomes. Methods This retrospective study included 83 patients with cervical cancer without distant metastasis who underwent primary concurrent chemoradiotherapy between 2013 and 2018. We analyzed the indicators of physical condition and muscle quantity using the SYNAPSE VINCENT software. Muscle mass and the relationship between treatment toxicity and prognosis were evaluated. Results The patients’ median age was 60 (range 33‒80) years. Cancer stage distribution was as follows: cT2b or higher, 84.3%; N1, 65.1%; and MA, 27.7%. The overall sarcopenia (skeletal muscle index [SMI] < 38.5) rate was 30.1%, and the rate was 33.9 and 22.2% in patients aged < 64 and ≥ 65 years, respectively. No correlation was observed between clinical stage and musculoskeletal indices. Treatment resulted in decreased body weight and SMI; after treatment, the sarcopenia rate increased to 37.3%. A higher intramuscular adipose tissue content (IMAC) reduced the number of chemotherapy cycles needed. Treatment-associated SMI decreases of ≥ 7% indicated poor prognosis, with significant differences in progression-free survival and overall survival ( p  = 0.013 and p  = 0.012, respectively). Patients who were very lean (body mass index < 18.5 kg/m 2 ) before treatment had a poor prognosis ( p  = 0.016 and p  < 0.001). Conclusions Our findings emphasize the importance of assessing original nutritional status and maintaining muscle mass and quality during the treatment of patients with cervical cancer.